Eli Lillyの空売り状況は、投資家がEli Lillyの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

Eli Lilly (NYSE:LLY) 株価情報, 空売り情報

Eli Lilly

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.

Eli Lilly and Co

News

Upgrades

Pre-Market Outlook

Analyst Ratings

Trading Ideas

HOOD

TTWO

主要なアナリストが株式レーティングを見直したトピックスを紹介する。アナリストのレーティング変更（格上げ・格下げを含む）はアナリストレーティングのページをご覧いただきたい。

ロビンフッドのアナリスト　市場への評価を変更

Equities

Markets

ASTS

DXCM

TSLA

先週木曜日、主要な米国株指数は反発を推移した。ダウ平均は0.2%高の3万9935ドル、一方でS＆P500は0.5%安の5392ドルで取引を終了した。ナスダックは0.9%安の17182ドルで終了した。

米国株式市場　テスラが市場を牽引　NBA契約でディズニーも上昇

Short Sellers

Short Ideas

Eli Lilly and Co (NYSE:LLY) のフロートに対する新しいショート比率は、前回の報告から14.06％上昇しています。同社は最近、ショートで売られた株は616万株あり、これは取引可能なすべての普通株の0.73％に相当します。平均してこの株のショートポジションをカバーするには、トレーダーは2.39日かかります。

イーライリリー社をショート比率から分析

Liberty Media Corporation - Series A Liberty Live Common Stock

Liberty Live Group

LIBERTY LIVE SERIES B by Liberty Media Corporation

Liberty Media Corporation - Series C Liberty Live Common Stock

Tidal Trust II Defiance Daily Target 2X Long LLY ETF

Eli Lilly And Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) announced on Monday that the highest approved doses of Zepbound (tirzepatide)—12.5 mg and 15 mg—would soon be available in single-dose vials for $499 per month through LillyDirect&#8217;s Self Pay Pharmacy Solutions and the Zepbound <a href="https://www.benzinga.com/topic/weight-loss" target="_blank" rel="noreferrer noopener">Self Pay Journey Program</a>.
Healthcare providers can begin prescribing the 12.5 mg and 15 mg vials on July 7; shipments to patients will begin in early August.
With the addition of these doses, every strength of Zepbound vial will be available for&nbsp;$499/month or less ($349&nbsp;for the 2.5 mg starter dose) to any eligible adult with obesity and a valid prescription, regardless of insurance.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/health-care/25/06/45834370/eli-lillys-obesity-drug-success-spurs-japanese-biotechs-anti-muscle-wasting-combo-therapy" rel="noreferrer noopener">Eli Lilly&#8217;s Obesity Drug Success Spurs Japanese Biotech&#8217;s Anti-Muscle-Wasting Combo Therapy</a>
Zepbound is an injectable prescription medicine that may help adults with obesity or some overweight adults with weight-related medical problems to lose excess body weight and <a href="https://www.benzinga.com/pressreleases/25/06/n45945218/lilly-to-offer-all-approved-doses-of-zepbound-tirzepatide-single-dose-vials-through-lillydirect-se" target="_blank" rel="noreferrer noopener">keep the weight off</a>.
It may also help adults with moderate-to-severe obstructive sleep apnea (OSA) and obesity to improve their OSA.
Patients with obesity who choose to self-pay will soon be able to access Zepbound single-dose vials, including 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg.
Patients on the 2.5 mg starter dose will pay&nbsp;$349&nbsp;for their first month, then&nbsp;$499&nbsp;per month for the 5 mg dose, which is the next step in treatment.
Through the Zepbound Self Pay Journey Program, designed to support patients throughout their obesity treatment journey, the 7.5 mg&nbsp;($599), 10 mg&nbsp;($699), 12.5 mg&nbsp;($849), and 15 mg&nbsp;($1,049)&nbsp;doses will be available at a reduced monthly cost of&nbsp;$499&nbsp;for the first fill and refills made within 45 days of the prior delivery.
The recommended starting dosage is 2.5 mg, which is taken once weekly for four weeks.
After four weeks, the dosage is increased to 5 mg. The health care provider may increase the dosage in 2.5 mg increments after at least four weeks on the current dose until the recommended maintenance dosage is achieved. 
The 2.5 mg starting dose is not an approved maintenance dose. The maximum dose is 15 mg.
Zepbound is also available in a single-dose pen (autoinjector) in 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, or 15 mg per 0.5 mL dose.
The 2.5 mg is a starting dose and not an approved maintenance dose. The recommended maintenance doses are 5 mg, 10 mg, or 15 mg, injected subcutaneously once per week for weight reduction and long-term maintenance, and 10 mg or 15 mg for OSA.
In a 72-week study of adults without diabetes, average weight loss was 15.0% (34 lbs) for 5 mg, 19.5% (44 lbs) for 10 mg, 20.9% (48 lbs) for 15 mg, and 3.1% (7 lbs) for placebo.
Average starting weights were 226.8 lbs for 5 mg, 233.3 lbs for 10 mg, 232.8 lbs for 15 mg, and 231.0 lbs for placebo.
In another 72-week study of adults with diabetes, average weight loss was 12.8% (28 lbs) for 10 mg, 14.7% (33 lbs) for 15 mg, and 3.2% (7 lbs) for placebo.
Further assessment of data for the 72-week study of adults without diabetes showed that the percent who saw ≥25% body weight loss (57-58 lbs) was 15.3% for 5 mg, 32.3% for 10 mg, 36.2% for 15 mg, and 1.5% for placebo.
Price Action: At the last check on Monday, LLY stock was up 0.75% at $825.50 during the premarket session.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/large-cap/25/06/45927887/novo-nordisk-moves-amycretin-into-phase-3-trials-for-weight-management-becomes-europes-largest-company" target="_blank" rel="noreferrer noopener">Novo Nordisk Moves Amycretin Into Phase 3 Trials For Weight Management, Becomes Europe&#8217;s Largest Company</a></li>
</ul>
Photo: Shutterstock

Biotech

Large Cap

Health Care

General

Eli Lilly Launches Flat Pricing For Zepbound, Capping Monthly Cost At $499

Health care providers can begin prescribing the 12.5 mg and 15 mg vials on July 7, and shipments to patients will begin in early August. With the addition of these doses, every strength of Zepbound vial will be available for $499/month or less ($349 for the 2.5 mg starter dose) to any eligible adult with obesity and a valid prescription, regardless of insurance.

Eli Lilly Announces That The Highest Approved Doses Of Zepbound (Tirzepatide)—12.5 mg And 15 mg—Will Soon Be Available In Single-dose Vials For $499 Per Month Through LillyDirect's Self Pay Pharmacy Solutions And The Zepbound Self Pay Journey Program

Benzinga examined the prospects for <a href="http://www.benzinga.com/trading-ideas" target="_blank" rel="noreferrer noopener">many investors' favorite stocks</a> over the last week — here's a look at some of our top stories.
Escalating geopolitical tensions in the Middle East — especially the Israel‑Iran conflict — and unexpectedly soft U.S. inflation data produced choppy market action this week. The S&amp;P 500 pulled back from all‑time highs as oil jumped above $70, marking its largest weekly gain in years.
Energy stocks led sector gains amid rising oil, while gold and silver rallied on demand for havens. Oracle (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ORCL#NYSE">ORCL</a>) stood out, climbing 20% after strong earnings. The U.S. dollar dipped to a three-year low against major currencies.
Looking ahead, investors are watching the Federal Reserve's upcoming meeting and U.S.–China trade discussions. Any change in rate guidance or geopolitical escalation could significantly sway market sentiment in the near term.
Benzinga provides daily reports on the stocks most popular with investors. Here are a few of this past week's most bullish and bearish posts that are worth another look.

The Bulls
<a href="https://www.benzinga.com/news/health-care/25/06/45927918/zepbound-put-eli-lilly-on-top-now-its-next-big-move-could-supercharge-the-stock">"Zepbound put Eli Lilly on top — now its next big move could supercharge the stock"</a>, by Surbhi Jain, reports that JPMorgan sees continued upside for Eli Lilly and Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) as strong Zepbound prescription growth positions the company for even greater gains from upcoming Orforglipron data, with the franchise projected to generate $79 billion in sales by 2030.
<a href="https://www.benzinga.com/trading-ideas/long-ideas/25/06/45909275/trumps-nuclear-play-fuels-oklos-stock-boom-and-the-ride">"Trump's nuclear play fuels Oklo's 566% stock boom — and the ride may be far from over"</a>, by Surbhi Jain, reports that Oklo Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OKLO#NYSE">OKLO</a>) shares surged 566% over the past year, fueled by Donald Trump's executive order accelerating nuclear development and a Pentagon microreactor contract, while bullish technicals suggest momentum may continue despite overbought signals.
<a href="https://www.benzinga.com/markets/tech/25/06/45885805/nvidias-jensen-huang-sparks-quantum-stock-frenzy">"Nvidia's Jensen Huang sparks quantum stock frenzy"</a>, by Erica Kollmann, reports that Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) CEO Jensen Huang declared quantum computing has reached an "inflection point," sparking sharp rallies in quantum stocks like Quantum Computing Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QUBT#NASDAQ">QUBT</a>) and Rigetti Computing (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGTI#NASDAQ">RGTI</a>).
For additional bullish calls of the past week, check out the following:
<a href="https://www.benzinga.com/markets/earnings/25/06/45893773/oracle-q4-earnings-revenue-eps-beat-estimates-cloud-infrastructure-growth-expected-to-accelerate-with-demand-skyrocketing">Oracle Q4 Earnings: Revenue, EPS Beat Estimates, Cloud Infrastructure Growth Expected To Accelerate With Demand ‘Skyrocketing'</a>
<a href="https://www.benzinga.com/trading-ideas/movers/25/06/45915485/rh-stock-surges-on-q1-earnings-beat-despite-worst-housing-market-in-50-years">RH Stock Surges On Q1 Earnings Beat Despite ‘Worst Housing Market' In 50 Years</a>
<a href="https://www.benzinga.com/trading-ideas/movers/25/06/45902627/us-listed-chinese-tech-and-ev-stocks-slide-as-trump-confirms-china-trade-deal">US Listed Chinese Tech And EV Stocks Slide As Trump Confirms China Trade Deal</a>

The Bears
<a href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/06/45888833/mcdonalds-just-got-hammered-by-weight-loss-drugs-twice">"McDonald's just got hammered by weight‑loss drugs — twice"</a>, by Piero Cingari, reports that McDonald's Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCD#NYSE">MCD</a>) could lose as much as 28 million annual visits — equal to $481.5 million in revenue — due to appetite‑suppressing GLP‑1 drugs, prompting a rare double downgrade to Sell as analysts warn of a potentially cumulative 10% hit to sales.
<a href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/06/45888497/bitcoin-probably-wont-fix-gamestops-troubles">"Bitcoin probably won't fix GameStop's troubles"</a>, by Chris Katje, reports that Wedbush analyst Michael Pachter maintains an Underperform rating on GameStop Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GME#NYSE">GME</a>), warning that its Bitcoin investment could add valuation volatility while its core video game business shows "no potential for a rebound."
<a href="https://www.benzinga.com/trading-ideas/short-ideas/25/06/45910389/short-seller-says-applovin-is-desperate-and-doomed-shares-slide">"Short seller says AppLovin is ‘desperate and doomed,' shares slide"</a>, by Surbhi Jain, reports that a noted short seller labeled AppLovin Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APP#NASDAQ">APP</a>) "desperate and doomed" — citing inflated marketing costs and slowing user growth — prompting a sharp share price decline.
For more bearish takes, be sure to see these posts:
<a href="https://www.benzinga.com/markets/earnings/25/06/45872191/gitlab-stock-drops-after-q1-report-q2-revenue-guidance-below-estimate">GitLab Stock Drops After Q1 Report, Q2 Revenue Guidance Below Estimate</a>
<a href="https://www.benzinga.com/trading-ideas/movers/25/06/45873964/steel-stocks-slide-on-potential-us-mexico-tariff-deal-report">Steel Stocks Slide On Potential US-Mexico Tariff Deal: Report</a>
<a href="https://www.benzinga.com/trading-ideas/technicals/25/06/45893129/stock-of-the-day-is-nrg-energy-losing-steam-chart-pattern-signals-trouble-ahead">Stock Of The Day: Is NRG Energy Losing Steam? Chart Pattern Signals Trouble Ahead</a>

Keep up with all the latest breaking news and trading ideas by following <a href="https://twitter.com/Benzinga" target="_blank" rel="noreferrer noopener">Benzinga</a><a href="http://twitter.com/Benzinga" target="_blank" rel="noreferrer noopener"> on X</a>.
Image created using artificial intelligence via Midjourney.

GTLB

NVDA

OKLO

ORCL

QUBT

RGTI

Benzinga Bulls And Bears: Eli Lilly, Okto, McDonalds — And Israel-Iran Conflict Sparks Oil Surge

Eli Lilly (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) has outperformed the market over the past 5 years by 24.18% on an annualized basis producing an average annual return of 38.13%. Currently, Eli Lilly has a market capitalization of $739.45 billion. 
Buying $1000 In LLY: If an investor had bought $1000 of LLY stock 5 years ago, it would be worth $5,817.45 today based on a price of $823.28 for LLY at the time of writing.
<h3>Eli Lilly's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1749830580_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In Eli Lilly 5 Years Ago Would Be Worth This Much Today

Eli Lilly &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) may be down over 8% in the past month and nearly 5% over the <a href="https://www.benzinga.com/quote/LLY/news">past five days</a>, but JPMorgan analyst Chris Schott isn't backing off. In fact, he's doubling down.
<h1 class="wp-block-heading">Zepbound's Momentum Keeps Eli Lilly In The Lead</h1>
With Zepbound continuing to dominate the GLP-1 obesity category and new catalysts on the horizon, JPMorgan sees Eli Lilly as still one of the top picks in the sector.
Prescriptions for both Zepbound and Mounjaro are running ahead of expectations in the second quarter, positioning Eli Lilly to beat and raise guidance throughout 2025. Even with the CVS formulary change (moving away from Zepbound) putting ~200,000 patients at risk, says the analyst, Eli Lilly's market share — currently around 70-75% of new patients — and strong momentum suggest the company will easily absorb the impact.
JPMorgan expects a 1.2 million prescription surge for Zepbound in the second quarter alone.
Read Also: <a href="https://www.benzinga.com/news/health-care/25/06/45887444/eli-lilly-inks-pact-with-juvena-therapeutics-to-develop-muscle-boosting-drugs">Eli Lilly Inks Pact With Juvena Therapeutics To Develop Muscle-Boosting Drugs</a>
<h1 class="wp-block-heading">All Eyes On Orforglipron</h1>
While Zepbound leads today, the next potential rally may be sparked by Orforglipron, Eli Lilly's small-molecule oral GLP-1. Phase 3 obesity data is expected in the third quarter, with a launch targeted for mid-2026.
JPMorgan sees Orforglipron as a key unlock in expanding access, both domestically and internationally, especially as pricing pressure eases and insurance coverage improves.
Schott projects the incretin franchise could hit a staggering $79 billion in sales by 2030. Backed by easing capacity constraints and broader payer adoption, this next leg of growth could fuel EPS at a 22.9% CAGR with ~50% operating margins.
<h1 class="wp-block-heading">Valuation Pullback = Opportunity?</h1>
Despite the long-term upside, Eli Lilly stock is down 8% in the past month — a rare breather after a blistering five-year rally of 465%. JPMorgan sees this dip as a buying opportunity. At ~34x/25x conservative 2025/2026 EPS estimates, Eli Lilly offers an attractive entry point with minimal loss-of-exclusivity risk and high-teen EPS growth potential through the early 2030s.
Even tariff risks are seen as manageable, with Lilly already shifting API production to the U.S. and building inventory buffers. In JPMorgan's view, Zepbound might be the star of today — but Orforglipron could soon take center stage and reignite the rally.
Read Also: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/06/45888833/mcdonalds-just-got-hammered-by-weight-loss-drugs-twice">McDonald&#8217;s Just Got Hammered By Weight-Loss Drugs — Twice</a></li>
</ul>
Photo: Shutterstock

Analyst Color

Long Ideas

Zepbound Put Eli Lilly On Top — Now Its Next Big Move Could Supercharge The Stock

Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVS#NYSE">NVS</a>) announced Thursday that it will advance subcutaneous and oral amycretin into phase 3 development <a href="https://www.benzinga.com/topic/weight-loss" target="_blank" rel="noreferrer noopener">in weight management</a>.
Amycretin is developed for subcutaneous and oral administration.
The decision to advance subcutaneous and oral amycretin into phase 3 is based on feedback received from regulatory authorities following end-of-phase 2 interactions for subcutaneous and oral amycretin in weight management.
Novo Nordisk <a target="_blank" href="https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=916348" rel="noreferrer noopener">plans</a> to initiate a phase 3 development program with amycretin for adults with overweight or obesity during the first quarter of 2026.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/health-care/25/06/45885869/novo-nordisk-deep-apple-launch-drug-discovery-alliance-for-weight-loss-oral-therapies" rel="noreferrer noopener">Novo Nordisk, Deep Apple Launch Drug Discovery Alliance For Weight Loss Oral Therapies</a>
Oral Amycretin Phase 1 trial evaluated the single-ascending dose and multiple-ascending doses for oral amycretin, up to 2 times 50 mg, in people with overweight or obesity, with a total treatment duration of up to 12 weeks.
The Subcutaneous Amycretin Phase 1b/2a trial investigated the safety, tolerability, pharmacokinetics, and proof-of-concept of once-weekly subcutaneous amycretin in overweight or obese people.
The trial was a combined single ascending dose, multiple ascending dose, and dose-response trial investigating three different maintenance doses with a total treatment duration of up to 36 weeks.
When evaluating the effects of treatment if all people adhered to treatment&nbsp;from a mean baseline body weight of 92.7 kg, people treated with amycretin achieved an estimated body weight loss of 9.7% on 1.25mg (20 weeks), 16.2% on 5mg (28 weeks) and 22.0% <a target="_blank" href="https://www.benzinga.com/general/biotech/25/01/43187095/novo-nordisks-weekly-amycretin-delivers-up-to-22-weight-loss-in-study-stock-soars" rel="noreferrer noopener">on 20mg (36 weeks)</a>.
People treated with a placebo experienced an estimated 1.9%, 2.3%, and 2.0% body weight gain, respectively.
After the update, Novo Nordisk again became the largest European company by market capitalization.
According <a target="_blank" href="https://www.benzinga.com/pro/feature/newsfeed" rel="noreferrer noopener">to Benzinga Pro</a>, Novo Nordisk&#8217;s market capitalization was $360.14 billion, compared with $351.9 billion for SAP SE (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SAP#NYSE">SAP</a>).
Since reaching a record high in June 2024, Novo has suffered a series of setbacks, including <a target="_blank" href="https://www.benzinga.com/24/12/42613036/novo-nordisks-hybrid-weight-loss-drug-falls-short-on-expectations-stock-plunges" rel="noreferrer noopener">disappointing clinical trial results</a> for its experimental obesity treatments and mounting competition from its U.S. rival, Eli Lilly And Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>).
In May, the drugmaker <a href="https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=916008" target="_blank" rel="noreferrer noopener">decided</a> to replace chief executive officer Lars Fruergaard Jorgensen. A search for a new CEO is ongoing.
Year to date, Novo Nordisk stock has fallen around 5.5%. In the past year, the stock has plunged approximately 43%.
Price Action: NVO stock is down 0.57% at $80.59&nbsp;at the last check on Friday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/large-cap/25/06/45910197/nvidia-just-partnered-with-a-weight-loss-giant-but-its-not-about-pills" target="_blank" rel="noreferrer noopener">Nvidia Just Partnered With A Weight-Loss Giant, But It&#8217;s Not About Pills</a></li>
</ul>
Photo: Shutterstock

Novo Nordisk Moves Amycretin Into Phase 3 Trials For Weight Management, Becomes Europe's Largest Company

Weight-loss drugs are suppressing appetites for millions of Americans, threatening to upend dining habits at fast-food chains and casting a shadow over the restaurant <a href="https://www.benzinga.com/general/restaurants">industry&#8217;s long-term growth.</a>
The stark warning came from Redburn Atlantic, which on Tuesday issued a rare double downgrade on McDonald's Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCD#NASDAQ">MCD</a>) — cutting the stock from Buy to Sell — amid growing concern that appetite-suppressing medications such as Novo Nordisk A/S&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) Wegovy and Eli Lilly and Co.&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) Zepbound are reshaping consumer behaviors.
Redburn's analyst Chris Luyckx said the behavioral effects of GLP-1 drugs are deeper than previously believed and could cause a cascading demand shock for restaurants reliant on habitual and group dining.
<h1 class="wp-block-heading">Is This The End Of America's Fast-Food Boom?</h1>
Luyckx estimates McDonald's could lose 28 million annual visits, amounting to $481.5 million in revenue — a 0.9% drag on its systemwide sales.
While that may appear manageable today, the analyst warned that the risk is cumulative, with broader shifts in eating habits already underway.
&#8220;A 1% drag today could easily build to 10% or more over time, particularly for brands skewed towards lower-income consumers or group occasions,&#8221; Luyckx said. 
&#8220;Despite best-in-class scale and global reach, McDonald's is showing cracks. Traffic is soft, especially in the U.S., where pricing fatigue and value perception are growing concerns,&#8221; he added.
Since 1977, the portion of calories Americans consume from restaurants has nearly tripled. But Redburn's report suggests that trend may be reversing. 
Currently, just 6% of U.S. adults are using GLP-1 medications, and 12% have ever taken them. Redburn's healthcare team expects penetration to reach 12% of non-type 2 diabetic obese adults by 2030.
<h1 class="wp-block-heading">Lunch and Dinner Under Pressure</h1>
&#8220;Lower-income users cut fast-food spending by 14%, double that of higher-income users, with the sharpest declines at lunch and dinner," Redburn's report said.
Among lower-income GLP-1 users, lunch spending drops by approximately 9%, while dinner falls by about 12%. 
These meals are typically the highest-volume periods for limited-service restaurants, leaving brands skewed toward those times disproportionately exposed.
Domino's Pizza Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DPZ#NYSE">DPZ</a>) and KFC face the highest relative risks. Domino's could see a $129.8 million revenue hit per year, or 1.4% of its system sales, while KFC may lose 1.2%.
Redburn initiated coverage on Domino&#8217;s Pizza with Sell rating and a 12-month price target of $340, implying 25% decline from current levels.
&#8220;Domino's, McDonald's and Pizza Hut face higher vulnerability given their high U.S. exposure, lower-income skews, daypart exposure and greater reliance on group occasions, where behavioural spillovers are more likely to occur,&#8221; said Luyckx.
Chains with more diversified traffic patterns, like Taco Bell and Chipotle Mexican Grill Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMG#NYSE">CMG</a>), are better positioned.
Taco Bell benefits from late-night traffic, where GLP-1 effects are minimal, while Chipotle's more affluent and health-conscious customer base shields it from the brunt of the shift. Chipotle's projected annual loss is $86.6 million, or just 0.8% of sales.
Read Now:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/05/45687453/starbucks-ends-25-star-bonus-for-reusable-cups-shifts-to-double-stars-as-ceo-cuts-perks-to-improve-profits">Starbucks Is Ending One Of Its Most Generous Loyalty Benefits As CEO Cuts Perks To Improve Profits</a> Photo New Africa On Shutterstock </li>
</ul>

Restaurants

Economics

McDonald's Just Got Hammered By Weight-Loss Drugs — Twice

Juvena Therapeutics, Inc. on Wednesday entered a global licensing and <a href="https://www.benzinga.com/topic/pharmaceuticals">multi-target research collaboration</a> with Eli Lilly And Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>). 
The two companies aim to develop and commercialize drug candidates that improve <a href="https://www.benzinga.com/topic/weight-loss" target="_blank" rel="noreferrer noopener">muscle health and body composition</a>.
Juvena <a href="https://www.globenewswire.com/news-release/2025/06/11/3097451/0/en/Juvena-Therapeutics-and-Lilly-Enter-Research-Collaboration-Focused-on-Muscle-Health.html" target="_blank" rel="noreferrer noopener">will</a> leverage JuvNET, an AI-enabled screening platform for mapping the therapeutic potential of stem cell-secreted proteins, developed by Juvena.
The collaboration will identify muscle-targeting drug candidates from Juvena's proprietary library of human stem-cell secreted proteins for improved body composition and muscle health.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/health-care/25/06/45834370/eli-lillys-obesity-drug-success-spurs-japanese-biotechs-anti-muscle-wasting-combo-therapy" rel="noreferrer noopener">Eli Lilly&#8217;s Obesity Drug Success Spurs Japanese Biotech&#8217;s Anti-Muscle-Wasting Combo Therapy</a>
Juvena Therapeutics is showcasing how its AI-driven discovery platform can accelerate the development of regenerative therapies for chronic diseases like obesity and frailty, Hanadie Yousef, co-founder and CEO of Juvena Therapeutics, explained.
The company focuses on pro-metabolic and muscle-regenerative treatments, driven by growing evidence that improving muscle health can enhance metabolism, mobility, and long-term disease resilience. By leveraging its proprietary library of stem-cell-derived proteins, Juvena aims to uncover novel therapeutic targets and bring more effective treatments to patients with greater precision and speed
Under the agreement, Juvena will receive an upfront payment, an equity investment, and potential development and commercialization milestone payments.
Juvena will grant Lilly an exclusive license to identified lead candidates and Lilly will be responsible for further research, development, and commercialization.
Juvena's pipeline of biologic drug candidates spans chronic muscle and obesity-related diseases.
In May, Juvena&nbsp;<a target="_blank" href="https://www.globenewswire.com/Tracker?data=iX2tz27fYL84UbK6_wCVTJ7yIVpwIMZKbweUugu-pA4cQi0X5LiEO8nbCAJwJFRgZcHp7pe86HK3INYNJ00gJ2yjcVKfrdygnUdtFaa9ADRvpqV4y3BYFN8Rayzoe9fdEiBHFunBqEJQ6g5AcZFxlhlbV2_AoNJIUWSLKe6mm3uATcMjcz0koumA04ZcuNGi8cm9r0mbr4S6le6HjgQkjOq3FqasqdK9kZWfLuv-FCWYiLXZ1y8uFIrIqdiGMxIK" rel="noreferrer noopener">announced</a>&nbsp;the first clinical trial for its lead program, JUV-161, engineered from a naturally secreted protein that enhances muscle regeneration and health.
They are also developing JUV-112, a lipolysis inducing, non-appetite suppressing, muscle sparing, obesity and metabolic disease preclinical candidate with an energy expenditure mechanism of action that is based on the discovery of a secreted protein that is orthogonal to incretins.
The company has also generated dozens of hits with tissue restorative benefits spanning pulmonary and hepatic fibrosis and osteoarthritis.
Last week, Swedish biopharmaceutical company&nbsp;Camurus AB&nbsp;entered a collaboration and <a target="_blank" href="https://www.benzinga.com/news/health-care/25/06/45769020/mounjaro-maker-eli-lilly-taps-swedish-firm-camurus-to-target-long-acting-obesity-market-in-870-million-deal" rel="noreferrer noopener">license agreement&nbsp;with&nbsp;Eli Lilly</a>.
Camurus granted Eli Lilly exclusive rights to research, develop, manufacture, and commercialize long-acting incretin products for cardiometabolic health based on Camurus' FluidCrystal technology.
The agreement&nbsp;comprises&nbsp;up to four Lilly proprietary drug compounds, selected from dual GIP and GLP-1 receptor agonists, triple GIP, glucagon, and GLP-1 receptor agonists, and an option to include amylin receptor agonists.
Price Action: Eli Lilly stock is up 0.75% at $813.28 at the last check on Wednesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/health-care/25/06/45844858/metsera-stock-rises-as-company-advances-obesity-pipeline-with-encouraging-weight-loss-data" target="_blank" rel="noreferrer noopener">Metsera Stock Rises As Company Advances Obesity Pipeline With Encouraging Weight Loss Data</a></li>
</ul>
Image: Shutterstock

Contracts

Eli Lilly Inks Pact With Juvena Therapeutics To Develop Muscle-Boosting Drugs

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders will search for circumstances when the market estimation of an option diverges heavily from its normal worth. High amounts of trading activity could push option prices to exaggerated or underestimated levels. 
Here's the list of options activity happening in today's session: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>HIMS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/13/25</td>
<td>$55.00</td>
<td>$82.5K</td>
<td>2.3K</td>
<td>4.5K</td>
</tr>
<tr>
<td>LQDA</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>07/18/25</td>
<td>$15.00</td>
<td>$27.9K</td>
<td>723</td>
<td>1.1K</td>
</tr>
<tr>
<td>VKTX</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>08/15/25</td>
<td>$27.50</td>
<td>$26.3K</td>
<td>3.6K</td>
<td>897</td>
</tr>
<tr>
<td>ALT</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>07/18/25</td>
<td>$6.00</td>
<td>$185.2K</td>
<td>930</td>
<td>783</td>
</tr>
<tr>
<td>UNH</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>12/19/25</td>
<td>$350.00</td>
<td>$80.9K</td>
<td>4.1K</td>
<td>712</td>
</tr>
<tr>
<td>MRK</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$115.00</td>
<td>$45.6K</td>
<td>2.5K</td>
<td>600</td>
</tr>
<tr>
<td>MRNA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$30.00</td>
<td>$27.2K</td>
<td>14.5K</td>
<td>195</td>
</tr>
<tr>
<td>INSM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>08/15/25</td>
<td>$75.00</td>
<td>$70.1K</td>
<td>420</td>
<td>157</td>
</tr>
<tr>
<td>NVO</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$75.00</td>
<td>$29.0K</td>
<td>1.6K</td>
<td>94</td>
</tr>
<tr>
<td>LLY</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>08/15/25</td>
<td>$770.00</td>
<td>$32.4K</td>
<td>222</td>
<td>87</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These itemized elaborations have been created using the accompanying table. 
• Regarding HIMS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>), we observe a call option sweep with bearish sentiment. It expires in 3 day(s) on June 13, 2025. Parties traded 500 contract(s) at a $55.00 strike. This particular call needed to be split into 67 different trades to become filled. The total cost received by the writing party (or parties) was $82.5K, with a price of $165.0 per contract. There were 2313 open contracts at this strike prior to today, and today 4580 contract(s) were bought and sold. 
• Regarding LQDA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LQDA#NASDAQ">LQDA</a>), we observe a put option trade with neutral sentiment. It expires in 38 day(s) on July 18, 2025. Parties traded 215 contract(s) at a $15.00 strike. The total cost received by the writing party (or parties) was $27.9K, with a price of $130.0 per contract. There were 723 open contracts at this strike prior to today, and today 1174 contract(s) were bought and sold. 
• Regarding VKTX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>), we observe a call option trade with neutral sentiment. It expires in 66 day(s) on August 15, 2025. Parties traded 40 contract(s) at a $27.50 strike. The total cost received by the writing party (or parties) was $26.3K, with a price of $659.0 per contract. There were 3634 open contracts at this strike prior to today, and today 897 contract(s) were bought and sold. 
• For ALT (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALT#NASDAQ">ALT</a>), we notice a put option sweep that happens to be bearish, expiring in 38 day(s) on July 18, 2025. This event was a transfer of 1122 contract(s) at a $6.00 strike. This particular put needed to be split into 62 different trades to become filled. The total cost received by the writing party (or parties) was $185.2K, with a price of $165.0 per contract. There were 930 open contracts at this strike prior to today, and today 783 contract(s) were bought and sold. 
• For UNH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>), we notice a call option trade that happens to be neutral, expiring in 192 day(s) on December 19, 2025. This event was a transfer of 40 contract(s) at a $350.00 strike. The total cost received by the writing party (or parties) was $80.9K, with a price of $2023.0 per contract. There were 4181 open contracts at this strike prior to today, and today 712 contract(s) were bought and sold. 
• For MRK (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>), we notice a call option sweep that happens to be bearish, expiring in 220 day(s) on January 16, 2026. This event was a transfer of 600 contract(s) at a $115.00 strike. This particular call needed to be split into 49 different trades to become filled. The total cost received by the writing party (or parties) was $45.6K, with a price of $76.0 per contract. There were 2577 open contracts at this strike prior to today, and today 600 contract(s) were bought and sold. 
• For MRNA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>), we notice a put option sweep that happens to be bullish, expiring in 101 day(s) on September 19, 2025. This event was a transfer of 50 contract(s) at a $30.00 strike. This particular put needed to be split into 8 different trades to become filled. The total cost received by the writing party (or parties) was $27.2K, with a price of $545.0 per contract. There were 14560 open contracts at this strike prior to today, and today 195 contract(s) were bought and sold. 
• For INSM (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>), we notice a call option sweep that happens to be bearish, expiring in 66 day(s) on August 15, 2025. This event was a transfer of 39 contract(s) at a $75.00 strike. This particular call needed to be split into 8 different trades to become filled. The total cost received by the writing party (or parties) was $70.1K, with a price of $1806.0 per contract. There were 420 open contracts at this strike prior to today, and today 157 contract(s) were bought and sold. 
• Regarding NVO (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>), we observe a call option trade with bullish sentiment. It expires in 220 day(s) on January 16, 2026. Parties traded 20 contract(s) at a $75.00 strike. The total cost received by the writing party (or parties) was $29.0K, with a price of $1450.0 per contract. There were 1606 open contracts at this strike prior to today, and today 94 contract(s) were bought and sold. 
• For LLY (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), we notice a put option sweep that happens to be bullish, expiring in 66 day(s) on August 15, 2025. This event was a transfer of 8 contract(s) at a $770.00 strike. This particular put needed to be split into 6 different trades to become filled. The total cost received by the writing party (or parties) was $32.4K, with a price of $4055.0 per contract. There were 222 open contracts at this strike prior to today, and today 87 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more about unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Options

Hims & Hers Health, Inc. Class A Common Stock

HIMS

INSM

LQDA

MRNA

VKTX

10 Health Care Stocks Whale Activity In Today's Session

On Monday, the U.S. Secretary of Health and Human Services, Robert F. Kennedy Jr., decided to fire all 17 members of the Advisory Committee on Immunization Practices, a panel that plays a key role in shaping U.S. vaccine policy.
What Happened: In an <a href="https://www.wsj.com/opinion/rfk-jr-hhs-moves-to-restore-public-trust-in-vaccines-45495112">op-ed</a> published in the Wall Street Journal, Kennedy said that this clean sweep was necessary in order to &#8220;re-establish public confidence in vaccine science.&#8221; He argued that the current panel had become a &#8220;rubber stamp for any vaccine&#8221; and was compromised by &#8220;persistent conflicts of interest.&#8221;
See Also: <a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/45852346/elon-musk-recently-said-yes-to-impeaching-trump-and-the-odds-of-that-happening-in-2025-rose-on-this-crypto-betting-market">Elon Musk Recently Said &#8216;Yes&#8217; To Impeaching Trump And The Odds Of That Happening In 2025 Rose On This Crypto Betting Market</a>
Kennedy, who has been a vocal anti-vaccine activist even before becoming the country&#8217;s top health official, hasn&#8217;t mentioned who will be appointed to the panel, but has said that the panel would convene within two weeks in Atlanta, according to a <a href="https://apnews.com/article/kennedy-cdc-acip-vaccines-3790c89f45b6314c5c7b686db0e3a8f9">report</a> from the Associated Press.
The ACIP advises the CDC on immunization schedules and insurance coverage guidance, and its recommendations thus carry immense sway on pharma and biotech stocks, especially those with a sizable vaccine portfolio.
Since the announcement was made, most stocks in the sector are in the red in after-hours trade,
<figure class="wp-block-table"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td class="has-text-align-center" data-align="center">Stock / ETF</td>
<td class="has-text-align-center" data-align="center">1 Day</td>
<td class="has-text-align-center" data-align="center">After Hours</td>
<td class="has-text-align-center" data-align="center">Year-To-Date</td>
</tr>
<tr>
<td class="has-text-align-center" data-align="center">Pfizer Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>)</td>
<td class="has-text-align-center" data-align="center">+2.66%</td>
<td class="has-text-align-center" data-align="center">-0.29%</td>
<td class="has-text-align-center" data-align="center">-9.92%</td>
</tr>
<tr>
<td class="has-text-align-center" data-align="center">Eli Lilly And Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>)</td>
<td class="has-text-align-center" data-align="center">+0.50%</td>
<td class="has-text-align-center" data-align="center">+0.15%</td>
<td class="has-text-align-center" data-align="center">-0.56%</td>
</tr>
<tr>
<td class="has-text-align-center" data-align="center">Moderna Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) </td>
<td class="has-text-align-center" data-align="center">+2.48%</td>
<td class="has-text-align-center" data-align="center">-0.85%</td>
<td class="has-text-align-center" data-align="center">-33.00%</td>
</tr>
<tr>
<td class="has-text-align-center" data-align="center">BioNTech SE ADR (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTX#NASDAQ">BNTX</a>)</td>
<td class="has-text-align-center" data-align="center">+0.44%</td>
<td class="has-text-align-center" data-align="center">-0.26%</td>
<td class="has-text-align-center" data-align="center">-5.49%</td>
</tr>
<tr>
<td class="has-text-align-center" data-align="center">iShares US Pharmaceuticals ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IHE#NYSE">IHE</a>)</td>
<td class="has-text-align-center" data-align="center">+0.24%</td>
<td class="has-text-align-center" data-align="center">-2.47%</td>
<td class="has-text-align-center" data-align="center">+1.26%</td>
</tr>
</tbody>
</table>
</figure>
Why It Matters: Kennedy has taken several steps against vaccination mandates in recent weeks, starting with the <a href="https://www.benzinga.com/25/05/45624037/robert-f-kennedy-jr-says-cdc-drops-covid-vaccine-for-healthy-pregnant-women-kids">removal of COVID vaccines</a> from the recommended immunization schedule for healthy pregnant women and children.
Around the same time, the Trump administration <a href="https://www.benzinga.com/government/regulations/25/05/45663794/hhs-cancels-590m-moderna-bird-flu-vaccine-deal-casting-uncertainty-over-pandemic-preparedness-effort">terminated a $600 million contract</a> with Moderna for developing an mRNA-based bird flu vaccine, which was part of former President Joe Biden&#8217;s pandemic preparedness efforts. 
Dr. Matthew Ferrari of the Pennsylvania State University <a href="https://www.benzinga.com/news/health-care/25/06/45810364/rfk-jr-champions-medical-freedom-while-curtailing-access-say-public-health-experts">criticized the health secretary</a>, saying that &#8220;If you restrict access, you necessarily restrict choice,&#8221; referring to the removal of COVID vaccines from the CDC schedule.
Price Action: The iShares U.S. Pharmaceuticals ETF tracks several of the heavyweights across pharma and biotech. On Monday, the fund was up 0.24%, trading at $66.45 per share, but is now down 2.47% after hours.
<figure class="wp-block-image size-large"><a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound"><img loading="lazy" decoding="async" width="1024" height="191" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/10010026/Screenshot-2025-06-10-at-10.30.08-AM-1024x191.png" alt="" class="wp-image-944102" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/10010026/Screenshot-2025-06-10-at-10.30.08-AM-1024x191.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/10010026/Screenshot-2025-06-10-at-10.30.08-AM-300x56.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/10010026/Screenshot-2025-06-10-at-10.30.08-AM-768x143.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/10010026/Screenshot-2025-06-10-at-10.30.08-AM.png 1178w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
The ETF is ranked in the 45th percentile according to Benzinga&#8217;s Edge Stock Rankings, and has a favorable price trend in the short term, but not so much in the medium and long term. Click <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">here</a> for deeper insights into the stock, as well as its alternatives. 
Photo Courtesy: Joshua Sukoff on Shutterstock.com
Read More: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/45852973/circle-ipo-success-suggests-markets-open-to-new-listings-especially-from-crypto-businesses-says-spac-king-chamath-palihapitiya">Circle IPO Success Suggests Markets Open To New Listings, Especially From Crypto Businesses, Says SPAC King Chamath Palihapitiya</a></li>
</ul>

Government

BNTX

iShares Dow Jones US Pharmaceuticals Index Fund

Robert Kennedy Jr Axes Entire CDC Vaccine Panel To 'Restore Public Trust' — Pfizer, Moderna, Other Biotech Stocks Drop In After-Hours Trading

Chugai Pharmaceutical Co. Ltd. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CHGCY#OTC">CHGCY</a>) believes its anti-muscle-wasting drug could be used alongside Eli Lilly And Co.&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) <a target="_blank" href="https://www.benzinga.com/topic/weight-loss" rel="noreferrer noopener">oral obesity pill</a>, orforglipron.
Roche Holdings AG (OTC:<a class="ticker" href="https://www.benzinga.com/stock/RHHBY#OTC">RHHBY</a>) is a major shareholder of Chugai, a Japanese pharmaceutical company. The company&#8217;s optimism stems from growing evidence that modern weight-loss drugs can lead to significant muscle loss, an issue Chugai thinks it can help address.
Hitoshi Iikura, a senior executive at Chugai, <a target="_blank" href="https://www.ft.com/content/4fd1fd94-0b70-48fb-861b-3bad6286ebae" rel="noreferrer noopener">told</a> the Financial Times the company has &#8220;high expectations&#8221; for combining GYM329, initially developed for spinal muscular atrophy (SMA), with orforglipron or similar therapies.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/health-care/25/06/45769020/mounjaro-maker-eli-lilly-taps-swedish-firm-camurus-to-target-long-acting-obesity-market-in-870-million-deal" rel="noreferrer noopener">Mounjaro Maker Eli Lilly Taps Swedish Firm Camurus To Target Long-Acting Obesity Market In $870-Million Deal</a>
Orforglipron, which Lilly licensed from Chugai, showed strong late-stage trial results, matching the safety and efficacy of popular injectables like Novo Nordisk A/S&#8217; (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) Wegovy and Ozempic and Lilly&#8217;s Zepbound and Mounjaro.
The drug significantly <a target="_blank" href="https://www.benzinga.com/general/biotech/25/04/44934811/eli-lilly-positioned-to-dominate-obesity-market-with-oral-option-analyst-initiates-with-confidence" rel="noreferrer noopener">reduced weight and blood sugar levels</a> and is expected to hit the market next year.
Chugai began developing orforglipron in 2003 as part of an effort to enhance diabetes treatments, aiming to make them longer-acting and tablet-based. Although obesity wasn&#8217;t an initial target, the company saw broader potential as research evolved. &#8220;We didn&#8217;t anticipate it but it&#8217;s ballooning,&#8221; Iikura said, referring to the unexpectedly large obesity market.
Studies suggest that 25% to 39% of weight loss from obesity drugs may be due to lean mass reduction, which includes muscle. Chugai argues that maintaining muscle mass is vital, especially for aging populations, and its GYM329 drug could be a key component in preventing this loss during weight-loss treatment.
Despite Chugai&#8217;s success, Roche had previously passed on orforglipron due to setbacks with an earlier weight-loss drug. At the time, much of the pharmaceutical industry was hesitant to enter the obesity space, except companies like Lilly and Novo Nordisk with strong metabolic disease portfolios.
However, with market interest and scientific breakthroughs accelerating, Roche reversed course in 2023 and <a target="_blank" href="https://www.benzinga.com/general/biotech/24/08/40422774/roche-misses-out-on-weight-loss-blockbuster-drug-now-playing-catch-up-in-booming-market" rel="noreferrer noopener">reentered the field</a>.
Meanwhile, Bloomberg <a target="_blank" href="https://www.bloomberg.com/news/articles/2025-06-07/lilly-s-obesity-drug-sales-rise-60-in-india-amid-rising-demand" rel="noreferrer noopener">reported</a> that Eli Lilly saw a 60% jump in sales of its weight-loss and diabetes drug Mounjaro in India in May compared to April, marking its second full month on the Indian market.
India has the third-largest obese population in the world.
According to market research firm Pharmarack Technologies, the U.S. drugmaker made 126 million rupees ($1.5 million) from Mounjaro injections last month.
Sales of the 5 mg dose more than doubled to 75 million rupees, while the 2.5 mg version brought in 51 million rupees.
According to the Indian Council of Medical Research (ICMR), there are 101 million people with diabetes in India. Of these, at least 40 million are on medication.
Vishal Manchanda, SVP of institutional research at Systematix Group,&nbsp;told&nbsp;Livemint that even if 0.5% of 40 million use Mounjaro, it would fetch Eli Lilly sales of <a target="_blank" href="https://www.benzinga.com/25/04/44824190/eli-lillys-mounjaro-launch-triggers-weight-loss-craze-in-india-novo-nordisk-seeks-to-move-up-wegovy-launch" rel="noreferrer noopener">$1.5 billion annually</a>.
Novo Nordisk&nbsp;is also trying to move up the launch of Wegovy in India to better compete with Lilly.
Price Action: LLY stock closed up 0.55% at $769.88 on Friday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/large-cap/25/06/45814068/novo-nordisks-wegovy-tied-to-increased-risk-of-rare-vision-loss-disorder-european-regulators-say" target="_blank" rel="noreferrer noopener">Novo Nordisk&#8217;s Wegovy Tied To Increased Risk Of Rare Vision-Loss Disorder, European Regulators Say</a></li>
</ul>
Photo via Shutterstock

CHGCY

RHHBY

Eli Lilly's Obesity Drug Success Spurs Japanese Biotech's Anti-Muscle-Wasting Combo Therapy

<a href="https://www.statnews.com/2025/06/05/glp-1-drugs-low-but-elevated-risk-of-age-related-macular-degeneration/?utm_campaign=rss" title="https://www.statnews.com/2025/06/05/glp-1-drugs-low-but-elevated-risk-of-age-related-macular-degeneration/?utm_campaign=rss">https://www.statnews.com/2025/06/05/glp-1-drugs-low-but-elevated-risk-of-age-related-macular-degeneration/?utm_campaign=rss</a>

'GLP-1 Drugs May Be Linked To Elevated Risk Of Serious Eye Disease, Study Finds' - STAT News

AnaptysBio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANAB#NASDAQ">ANAB</a>) on Tuesday released updated data from the Phase 2b trial of rosnilimab, a PD-1 depleter and agonist, for <a href="https://www.benzinga.com/general/health-care" target="_blank" rel="noreferrer noopener">rheumatoid arthritis</a>.
In the 424-patient 2b trial, rosnilimab achieved JAK-like efficacy on multiple clinically meaningful measures, including low disease activity (LDA) and remission on the Clinical Disease Activity Index (CDAI), as well as ACR70 response, <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/g45757627/anaptys-announces-positive-rosnilimab-data-updated-through-six-months-in-robust-phase-2b-trial-in-" rel="noreferrer noopener">over six months</a>.
Furthermore, responses were then durable for at least two months off the drug.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/12/42445688/anaptysbio-discontinues-investment-in-eczema-candidate-after-disappointing-data" rel="noreferrer noopener">AnaptysBio Discontinues Investment In Eczema Candidate After Disappointing Data</a>
Rosnilimab was safe and well tolerated, particularly compared to standard-of-care biologics or JAKs.
All three doses (100mg Q4W, 400mg Q4W, 600mg Q2W) achieved statistically significant reductions in DAS-28 CRP and ACR20 at Week 12 versus placebo.
CDAI LDA (≤10) was achieved by 45% of 318 rosnilimab patients by Week 12, increasing to 69% (220 responders) across all doses by Week 14.
The company aims to complete its Phase 2 study for rosnilimab in ulcerative colitis/UC, with initial data expected in the fourth quarter of 2025.
As of the March 11, 2025&nbsp;data cutoff date, 83% were still in LDA at Week 34 across all doses. Of the remaining 17% of patients who did not sustain CDAI LDA at Week 34, most remained near the cutoff of CDAI=10, with a median CDAI of 13.
Rosnilimab demonstrated clinically meaningful improvements that deepened through Week 28 across multiple validated patient-reported outcomes, including the pain visual analog scale (VAS) and the health assessment questionnaire, or HAQ-Disability Index (DI), a self-reporting tool to measure function and disability.
HC Wainwright analyst Emily Bodnar wrote on Wednesday, &#8220;Given the data showcase a positive holistic story for rosnilimab in RA, we are increasingly positive on upcoming UC data.&#8221;
Bodnar upgraded AnaptysBio from Neutral to Buy, raising the price target<a href="https://www.benzinga.com/quote/ANAB/analyst-ratings" target="_blank" rel="noreferrer noopener"> from $22 to $38</a>.
HC Wainwright Highlights Competitor Datasets
Data using non-responder imputation (NRI) from Week 24 of the SELECT-CHOICE trial, which compared AbbVie Inc&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) Rinvoq vs Bristol Myers Squibb&nbsp;&amp; Co&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) Orencia in rheumatoid arthritis (RA), showed similar results for both drugs. These findings align with the results seen for the company&#8217;s rosnilimab at Week 28, even though about 29% of patients had previously been treated with JAK inhibitors.
In contrast, Eli Lilly And Co&#8216;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) now-discontinued PD-1 agonist peresolimab showed a drop in CDAI LDA rates—from 55% at Week 14 to 37% at Week 24. This is notably lower than the 53–63% range reported for rosnilimab at Week 28.
Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) is also set to present early data for its PD-1 agonist at the upcoming EULAR conference, though its study is smaller than AnaptysBio&#8217;s.
Price Action: ANAB stock is down 12.1% at $20.66 at the last check on Wednesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/06/45769045/tariffs-ai-and-trade-war-apples-smartphone-growth-to-take-a-hit-experts-say" target="_blank" rel="noreferrer noopener">Tariffs, AI And Trade War: Apple&#8217;s Smartphone Growth To Take A Hit, Experts Say</a></li>
</ul>
Photo: Shutterstock

Movers

ABBV

ANAB

AnaptysBio's Arthritis Drug Matches Top Therapies In Phase 2 Trial, Analyst Sees Turning Point

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders will search for circumstances when the market estimation of an option diverges heavily from its normal worth. High amounts of trading activity could push option prices to exaggerated or underestimated levels. 
Below are some instances of options activity happening in the Health Care sector: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>NTRA</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$175.00</td>
<td>$36.9K</td>
<td>10</td>
<td>1.3K</td>
</tr>
<tr>
<td>TEVA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$18.00</td>
<td>$25.4K</td>
<td>49.9K</td>
<td>898</td>
</tr>
<tr>
<td>SRDX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>08/15/25</td>
<td>$30.00</td>
<td>$190.0K</td>
<td>502</td>
<td>500</td>
</tr>
<tr>
<td>UNH</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>07/18/25</td>
<td>$310.00</td>
<td>$43.5K</td>
<td>3.0K</td>
<td>494</td>
</tr>
<tr>
<td>AKBA</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$2.50</td>
<td>$31.0K</td>
<td>438</td>
<td>350</td>
</tr>
<tr>
<td>MRK</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$70.00</td>
<td>$88.3K</td>
<td>576</td>
<td>217</td>
</tr>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/19/25</td>
<td>$710.00</td>
<td>$63.4K</td>
<td>25</td>
<td>13</td>
</tr>
<tr>
<td>MRNA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$115.00</td>
<td>$87.5K</td>
<td>12</td>
<td>10</td>
</tr>
<tr>
<td>ABBV</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>09/18/26</td>
<td>$120.00</td>
<td>$35.6K</td>
<td>0</td>
<td>5</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These itemized elaborations have been created using the accompanying table. 
• For NTRA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRA#NASDAQ">NTRA</a>), we notice a call option trade that happens to be bullish, expiring in 107 day(s) on September 19, 2025. This event was a transfer of 26 contract(s) at a $175.00 strike. The total cost received by the writing party (or parties) was $36.9K, with a price of $1420.0 per contract. There were 10 open contracts at this strike prior to today, and today 1350 contract(s) were bought and sold. 
• For TEVA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>), we notice a call option sweep that happens to be bullish, expiring in 16 day(s) on June 20, 2025. This event was a transfer of 750 contract(s) at a $18.00 strike. This particular call needed to be split into 8 different trades to become filled. The total cost received by the writing party (or parties) was $25.4K, with a price of $34.0 per contract. There were 49987 open contracts at this strike prior to today, and today 898 contract(s) were bought and sold. 
• Regarding SRDX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRDX#NASDAQ">SRDX</a>), we observe a call option trade with bullish sentiment. It expires in 72 day(s) on August 15, 2025. Parties traded 500 contract(s) at a $30.00 strike. The total cost received by the writing party (or parties) was $190.0K, with a price of $380.0 per contract. There were 502 open contracts at this strike prior to today, and today 500 contract(s) were bought and sold. 
• Regarding UNH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>), we observe a call option sweep with bullish sentiment. It expires in 44 day(s) on July 18, 2025. Parties traded 38 contract(s) at a $310.00 strike. This particular call needed to be split into 4 different trades to become filled. The total cost received by the writing party (or parties) was $43.5K, with a price of $1145.0 per contract. There were 3038 open contracts at this strike prior to today, and today 494 contract(s) were bought and sold. 
• Regarding AKBA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKBA#NASDAQ">AKBA</a>), we observe a call option trade with bullish sentiment. It expires in 226 day(s) on January 16, 2026. Parties traded 200 contract(s) at a $2.50 strike. The total cost received by the writing party (or parties) was $31.0K, with a price of $155.0 per contract. There were 438 open contracts at this strike prior to today, and today 350 contract(s) were bought and sold. 
• Regarding MRK (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>), we observe a call option trade with bearish sentiment. It expires in 16 day(s) on June 20, 2025. Parties traded 100 contract(s) at a $70.00 strike. The total cost received by the writing party (or parties) was $88.3K, with a price of $883.0 per contract. There were 576 open contracts at this strike prior to today, and today 217 contract(s) were bought and sold. 
• For LLY (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), we notice a call option trade that happens to be bullish, expiring in 198 day(s) on December 19, 2025. This event was a transfer of 5 contract(s) at a $710.00 strike. The total cost received by the writing party (or parties) was $63.4K, with a price of $12690.0 per contract. There were 25 open contracts at this strike prior to today, and today 13 contract(s) were bought and sold. 
• For MRNA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>), we notice a put option sweep that happens to be neutral, expiring in 226 day(s) on January 16, 2026. This event was a transfer of 10 contract(s) at a $115.00 strike. This particular put needed to be split into 5 different trades to become filled. The total cost received by the writing party (or parties) was $87.5K, with a price of $8753.0 per contract. There were 12 open contracts at this strike prior to today, and today 10 contract(s) were bought and sold. 
• For ABBV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>), we notice a call option trade that happens to be neutral, expiring in 471 day(s) on September 18, 2026. This event was a transfer of 5 contract(s) at a $120.00 strike. The total cost received by the writing party (or parties) was $35.6K, with a price of $7130.0 per contract. There were 0 open contracts at this strike prior to today, and today 5 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more about unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AKBA

NTRA

SRDX

TEVA

9 Health Care Stocks Whale Activity In Today's Session

Swedish biopharmaceutical company Camurus AB entered a collaboration and license agreement with Eli Lilly and Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) on Tuesday.
Camurus granted Eli Lilly exclusive, worldwide rights to research, develop, manufacture, and commercialize <a href="https://www.benzinga.com/topic/weight-loss" target="_blank" rel="noreferrer noopener">long-acting incretin</a> products for cardiometabolic health based on Camurus&#8217; FluidCrystal technology.
The agreement <a target="_blank" href="https://www.camurus.com/media/press-releases/2025/camurus-and-lilly-enter-collaboration-and-license-agreement-for-long-acting-fluidcrystal-incretins/" rel="noreferrer noopener">comprises</a> up to four Lilly proprietary drug compounds, selected from dual GIP and GLP-1 receptor agonists, triple GIP, glucagon, and GLP-1 receptor agonists, and an option to include amylin receptor agonists.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/05/45341500/eli-lillys-zepbound-shows-superior-weight-loss-over-novo-nordisks-wegovy-in-head-to-head-trial" rel="noreferrer noopener">Eli Lilly&#8217;s Zepbound Shows Superior Weight Loss Over Novo Nordisk&#8217;s Wegovy In Head-To-Head Trial</a>
Camurus' FluidCrystal technology is designed to deliver therapeutic levels of drug substance over extended periods – from days to months – with a single injection using a prefilled syringe or autoinjector pen.
Upon contact with bodily fluids in the tissue, the lipid solution transforms into a liquid crystalline gel that quickly and effectively encapsulates the active ingredient. The drug is slowly released as the liquid crystalline matrix gradually degrades in the tissue.
The technology is commercially and regulatory validated by market approvals and product sales in Europe, the US, and Australia.
In return for granting Lilly the license to use the FluidCrystal technology for the selected incretin drug compounds for cardiometabolic health, Camurus is eligible to receive up to&nbsp;$290 million&nbsp;in upfront, development, and regulatory milestone payments, $580 million in sales-based milestone payments, and tiered mid-single-digit royalties on global net product sales.
In May, Eli Lilly agreed to acquire&nbsp;SiteOne Therapeutics, Inc., a private biotechnology company developing small-molecule inhibitors of sodium channels to treat pain and other neuronal&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/25/05/45629147/breaking-the-pain-barrier-lillys-acquisition-of-siteone-aims-for-opioid-alternatives" rel="noreferrer noopener">hyperexcitability disorders</a>.
The transaction includes STC-004, a Phase 2 ready Nav1.8 inhibitor being&nbsp;studied for pain.
STC-004 may represent a next-generation, non-opioid treatment for patients suffering from chronic pain.
In May, Eli Lilly entered into a strategic global research collaboration and licensing agreement with Rznomics Inc., a South Korea-based biopharmaceutical company specializing <a href="https://www.benzinga.com/25/05/45450675/eli-lilly-collaborates-with-south-korea-based-rznomics-for-rna-editing-therapies-for-hearing-loss-treatment-in-over-13-billion-pact" target="_blank" rel="noopener">in RNA-based therapeutics</a>.
The agreement focuses on developing and commercializing RNA-editing therapies using Rznomics&#8217; proprietary trans-splicing ribozyme platform.
The collaboration&nbsp;<a target="_blank" href="https://www.prnewswire.com/news-releases/rznomics-enters-global-licensing-agreement-with-eli-lilly-for-rna-editing-therapeutics-302456852.html?tblci=GiCUX7wvU_AgmIIiQduNYr6JQuJQLy6SZJGvpyeZuCzyqiCN1VcoxvTN4f7-y-PqATDviEo" rel="noreferrer noopener">focuses</a>&nbsp;on discovering and developing RNA-editing therapeutics for sensorineural hearing loss. Rznomics will conduct early-stage research according to the jointly approved research plans, while Lilly will assume responsibility for further development and commercialization.
Price Action: At the last check on Wednesday, LLY stock was up 0.40% at $753.80 during the premarket session.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/dividends/25/06/45767454/autoliv-boosts-shareholder-returns-with-21-dividend-hike-new-2-5-billion-buyback-program" target="_blank" rel="noreferrer noopener">Autoliv Boosts Shareholder Returns With 21% Dividend Hike, New $2.5 Billion Buyback Program</a></li>
</ul>
Photo: Shutterstock

Mounjaro Maker Eli Lilly Taps Swedish Firm Camurus To Target Long-Acting Obesity Market In $870-Million Deal

<a href="https://www.dailymail.co.uk/health/article-14773791/ozempic-weight-loss-drugs-kidney-cancer-risk-study.html" title="https://www.dailymail.co.uk/health/article-14773791/ozempic-weight-loss-drugs-kidney-cancer-risk-study.html">https://www.dailymail.co.uk/health/article-14773791/ozempic-weight-loss-drugs-kidney-cancer-risk-study.html</a>

"Exclusive: Ozempic Linked To 'Silent Cancer' That Is Rising In Young People As Doctors Issue Shock Warning" - DailyMail+

Summer is almost here, and investors are hunting for fresh opportunities after the S&amp;P 500 logged its strongest <a href="https://www.benzinga.com/markets/equities/25/05/45704748/magnificent-seven-drive-wall-streets-rally-nvidia-notches-best-month-in-a-year-this-week-in-markets">month since November 2023. </a>
According to Seasonax data, looking at 97 years of history, the S&amp;P 500 averages a 0.7% gain in June. In recent times, performance has been even better: over the past six years, the index has ended June higher five times, with an average return of 2.1%.
Thus, June has historically brought more gains than pain, and certain S&amp;P 500 stocks have a consistent track record of outperforming in this early-summer stretch.
<h3 class="wp-block-heading">Top 10 June Stocks Based On 10-Year Seasonal Performance</h3>
An analysis of S&amp;P 500 components between June 2 and July 2 over the past 10 years reveals clear outperformers. Here are the top 10 stocks ranked by average return during this 30-day window. 
Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) is by far the top June performer, with an average return of 14.5%, beating the S&amp;P 500 by a wide margin. It closed positively in 8 out of the last 10 Junes, with the best return — a 37.1% rally — coming in 2023.
Eli Lilly &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) has been the most consistent performer on this list, with 9 wins in 10 years. Its June gains have averaged 6.2% over the past decade, with a peak return of 17.5% in 2021 and a minimal drawdown of -2.2% in 2019.
Adobe Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADBE#NASDAQ">ADBE</a>) also ranks high with a 5.6% average return. Notably, in the last two Junes, the tech company rose by 17% and 24.9% respectively.
<figure class="wp-block-table is-style-stripes"> 
<table class="has-fixed-layout">
<thead>
<tr>
<th>Stock</th>
<th>Avg Return</th>
<th>Win Rate</th>
<th>Max Gain</th>
<th>Worst Drop</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tesla </td>
<td>+14.5%</td>
<td>8/10</td>
<td>+37.1%</td>
<td>-9.8%</td>
</tr>
<tr>
<td>Eli Lilly </td>
<td>+6.2%</td>
<td>9/10</td>
<td>+17.5%</td>
<td>-2.2%</td>
</tr>
<tr>
<td>Adobe </td>
<td>+5.7%</td>
<td>6/10</td>
<td>+29.3%</td>
<td>-14.7%</td>
</tr>
<tr>
<td>Oracle Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ORCL#NASDAQ">ORCL</a>)</td>
<td>+4.9%</td>
<td>7/10</td>
<td>+20.1%</td>
<td>-7.6%</td>
</tr>
<tr>
<td>Generac Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GNRC#NYSE">GNRC</a>)</td>
<td>+4.9%</td>
<td>6/10</td>
<td>+31.2%</td>
<td>-19.4%</td>
</tr>
<tr>
<td>Amazon.com Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>)</td>
<td>+4.3%</td>
<td>7/10</td>
<td>+16.9%</td>
<td>-9.6%</td>
</tr>
<tr>
<td>Digital Realty Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DLR#NYSE">DLR</a>)</td>
<td>+4.0%</td>
<td>7/10</td>
<td>+15.5%</td>
<td>-6.2%</td>
</tr>
<tr>
<td>Domino's Pizza Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DPZ#NASDAQ">DPZ</a>)</td>
<td>+4.0%</td>
<td>6/10</td>
<td>+11.5%</td>
<td>-5.5%</td>
</tr>
<tr>
<td>Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>)</td>
<td>+3.7%</td>
<td>5/10</td>
<td>+17.0%</td>
<td>-7.7%</td>
</tr>
<tr>
<td>Fair Isaac Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FICO#NYSE">FICO</a>)</td>
<td>+3.7%</td>
<td>8/10</td>
<td>+18.2%</td>
<td>-1.96%</td>
</tr>
</tbody>
</table>
</figure>
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/etfs/new-etfs/25/06/45722678/magnificent-seven-closed-a-blockbuster-may-added-nearly-2-trillion-in-market-value">Magnificent Seven Closed A Blockbuster May, Added Nearly $2 Trillion In Market Value </a></li>
</ul>
Photo: Shutterstock

AAPL

ADBE

AMZN

FICO

GNRC

Looking For Summer Seasonal Gains? Here Are 10 S&P 500 Stocks That Historically Rallied In June

Penny stock Veru Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERU#NASDAQ">VERU</a>) on Wednesday released topline safety results from the Phase 2b QUALITY study of enobosarm 3mg, enobosarm 6mg, or placebo to enhance fat loss and prevent muscle loss in patients over 60 years receiving Novo Nordisk A/S&#8217; (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) Wegovy (semaglutide) for <a target="_blank" href="https://www.benzinga.com/topic/weight-loss" rel="noreferrer noopener">chronic weight management</a>.
The enobosarm and semaglutide GLP-1 RA combination had a favorable safety profile in the trial.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/01/43237532/veru-shares-tumble-despite-enobosarms-lean-muscle-preservation-breakthrough" rel="noreferrer noopener">Veru Shares Tumble Despite Enobosarm&#8217;s Lean Muscle Preservation Breakthrough</a>
There were no increases in gastrointestinal side effects. There is also no evidence of drug-induced liver injury, or increases in obstructive sleep apnea at any dose of enobosarm compared to the placebo. 
There were no AEs of increases in prostate-specific antigen in men. There were no AEs related to masculinization in women. There were no reports of suicidal ideation observed.
No treatment-related serious adverse events (SAEs) were observed in the QUALITY study.
At the proposed Phase 3 program dose of enobosarm 3mg, one subject experienced an adverse event of a transient, mild increase in alanine aminotransferase (ALT), which returned to baseline while remaining on enobosarm.
There were no accompanying increases in aspartate aminotransferase (AST), alkaline phosphatase, or total bilirubin.
The data shows that adding enobosarm 3mg to <a href="https://www.benzinga.com/pressreleases/25/05/g45639117/veru-reports-positive-safety-results-from-phase-2b-quality-study-enobosarm-added-to-semaglutide-le" target="_blank" rel="noreferrer noopener">semaglutide</a> created a more selective weight loss profile, with 99.1% of weight loss coming from fat rather than muscle compared to 68% in the semaglutide plus placebo arm.
The&nbsp;Stair Climb Test&nbsp;showed that 42.6% of semaglutide-only patients experienced significant functional decline equivalent to 7.5 years of aging, while only 16% of the enobosarm 3mg combination group showed a similar decline, translating to a 62.4% relative reduction in functional deterioration.
The enobosarm 6mg + semaglutide dose did not provide any additional benefit over the 3mg dose in preserving lean mass.
The company plans to propose a Phase 3 program similar to the Phase 2b QUALITY trial in older patients. The GLP-1 RA may be either Wegovy and/or Eli Lilly And Co&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) Zepbound (tirzepatide).
Price Action: VERU stock is up 22.5% at 62 cents at the last check Wednesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/25/05/45643704/ford-recalls-11-million-vehicles-for-camera-software-issue-report" target="_blank" rel="noreferrer noopener">Ford Recalls 1.1 Million Vehicles For Camera Software Issue: Report</a></li>
</ul>
Image: Shutterstock

VERU

Veru's Enobosarm Shows Muscle In Wegovy Combo Trial

In the current market session, Eli Lilly Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) price is at $725.96, after a 1.72% increase. However, over the past month, the stock decreased by 17.99%, and in the past year, by 10.54%. Shareholders might be interested in knowing whether the stock is undervalued, even if the company is performing up to par in the current session. 

<img src="https://www.benzinga.com/files/images/story/2025/1748376027_0.png" alt="Past Year Chart" />

<h3>Eli Lilly P/E Compared to Competitors</h3>
The P/E ratio measures the current share price to the company's EPS. It is used by long-term investors to analyze the company's current performance against it's past earnings, historical data and aggregate market data for the industry or the indices, such as S&amp;P 500. A higher P/E indicates that investors expect the company to perform better in the future, and the stock is probably overvalued, but not necessarily. It also could indicate that investors are willing to pay a higher share price currently, because they expect the company to perform better in the upcoming quarters. This leads investors to also remain optimistic about rising dividends in the future. 
Compared to the aggregate P/E ratio of 26.38 in the Pharmaceuticals industry, Eli Lilly Inc. has a higher P/E ratio of 58.07. Shareholders might be inclined to think that Eli Lilly Inc. might perform better than its industry group. It's also possible that the stock is overvalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1748376027_1.png" alt="Guage" />

In conclusion, the price-to-earnings ratio is a useful metric for analyzing a company's market performance, but it has its limitations. While a lower P/E can indicate that a company is undervalued, it can also suggest that shareholders do not expect future growth. Additionally, the P/E ratio should not be used in isolation, as other factors such as industry trends and business cycles can also impact a company's stock price. Therefore, investors should use the P/E ratio in conjunction with other financial metrics and qualitative analysis to make informed investment decisions.

Intraday Update

P/E Ratio Insights for Eli Lilly

Eli Lilly and Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) is on track to close one of its worst months ever after slashing its full-year profit outlook despite beating <a href="https://www.benzinga.com/general/biotech/25/05/45176293/eli-lilly-stock-offers-buying-opportunity-for-goldman-sachs-concerns-over-cvs-setback-are-overblown-analysts-say">first-quarter earnings estimates. </a>
But a glimmer of hope lies ahead, as June historically stands out as the drugmaker's best month of the year.
Shares of Eli Lilly are down 19% in May, pacing for their worst monthly performance since February 2009. However, the underperformance compared to the broader market has been even more severe.
The stock has lagged the S&amp;P 500 Index by 23.8% this month — the steepest relative decline since August 2000 and the second-largest since the company went public in 1970.
<h3 class="wp-block-heading">Chart: Eli Lilly Suffered One Of Its Worst Months Ever</h3>
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="535" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/27145342/image-343-1024x535.png" alt="" class="wp-image-928926" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/27145342/image-343-1024x535.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/27145342/image-343-300x157.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/27145342/image-343-768x401.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/27145342/image-343-1536x803.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/27145342/image-343-2048x1070.png 2048w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
<h3 class="wp-block-heading">What Sparked The Selloff?</h3>
The sharp move followed the company's May 1 quarterly earnings. While Lilly posted better-than-expected first-quarter results, the stock plunged 12% that day — the worst single-session drop since August 2000.
The decline was triggered by a sharp cut in the company's full-year profit forecast. Eli Lilly cited $1.57 billion in acquired in-process research and development (IPR&amp;D) charges, primarily tied to its acquisition of a cancer therapy from Scorpion Therapeutics. While sales guidance remained unchanged, full-year profit expectations were revised downward to reflect those R&amp;D costs.
For 2025, Eli Lilly projects revenue between $58 billion and $61 billion, implying a 32% year-over-year increase.
&#8220;Expect volatility, take advantage of moment of weakness, as long as there is not a new, fundamental crack in the story,&#8221; said Bank of America analyst Tim Anderson. The firm reaffirmed its 12-month price target of $1,000, suggesting a 38% upside from current levels.
<h3 class="wp-block-heading">Could June Offer Relief?</h3>
While May has battered Lilly shareholders, June has historically brought better fortune. Over the past 30 years, shares have gained an average of 2.94% during the month, according to TradingView data.
June is statistically Eli Lilly's best month, with a 67% chance of closing higher. 
Even more notable: the past five Junes have all ended in the green. The best June performance came in 2000 when the stock surged 28.1%. Only two Junes in recent history delivered double-digit losses — in 2001 and 2019, both dropping 10.6%.
There's precedent for a bounce. In 1997 and 2003, Eli Lilly dropped more than 10% in May. In both cases, shares recovered in June with gains of 3.9% and 14.1%, respectively.
<figure class="wp-block-table is-style-stripes"> 
<table class="has-fixed-layout">
<thead>
<tr>
<th>Year</th>
<th>$LLY June Performance</th>
</tr>
</thead>
<tbody>
<tr>
<td>1995</td>
<td>3.00%</td>
</tr>
<tr>
<td>1996</td>
<td>0.94%</td>
</tr>
<tr>
<td>1997</td>
<td>12.65%</td>
</tr>
<tr>
<td>1998</td>
<td>3.85%</td>
</tr>
<tr>
<td>1999</td>
<td>-4.91%</td>
</tr>
<tr>
<td>2000</td>
<td>28.14%</td>
</tr>
<tr>
<td>2001</td>
<td>-10.58%</td>
</tr>
<tr>
<td>2002</td>
<td>-5.98%</td>
</tr>
<tr>
<td>2003</td>
<td>14.10%</td>
</tr>
<tr>
<td>2004</td>
<td>-6.78%</td>
</tr>
<tr>
<td>2005</td>
<td>-4.43%</td>
</tr>
<tr>
<td>2006</td>
<td>7.02%</td>
</tr>
<tr>
<td>2007</td>
<td>-2.95%</td>
</tr>
<tr>
<td>2008</td>
<td>4.90%</td>
</tr>
<tr>
<td>2009</td>
<td>0.18%</td>
</tr>
<tr>
<td>2010</td>
<td>7.98%</td>
</tr>
<tr>
<td>2011</td>
<td>-0.66%</td>
</tr>
<tr>
<td>2012</td>
<td>0.80%</td>
</tr>
<tr>
<td>2013</td>
<td>-6.19%</td>
</tr>
<tr>
<td>2014</td>
<td>1.92%</td>
</tr>
<tr>
<td>2015</td>
<td>8.09%</td>
</tr>
<tr>
<td>2016</td>
<td>4.86%</td>
</tr>
<tr>
<td>2017</td>
<td>2.94%</td>
</tr>
<tr>
<td>2018</td>
<td>-0.14%</td>
</tr>
<tr>
<td>2019</td>
<td>-10.60%</td>
</tr>
<tr>
<td>2020</td>
<td>5.40%</td>
</tr>
<tr>
<td>2021</td>
<td>12.41%</td>
</tr>
<tr>
<td>2022</td>
<td>12.92%</td>
</tr>
<tr>
<td>2023</td>
<td>2.56%</td>
</tr>
<tr>
<td>2024</td>
<td>6.67%</td>
</tr>
</tbody>
<tfoot>
<tr>
<td>Average</td>
<td>2.94%</td>
</tr>
</tfoot>
</table>
</figure>
Read now: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/government/regulations/25/05/45574763/goldman-sachs-defense-stock-golden-dome">Goldman Sachs Taps This Defense Stock As Prime Beneficiary Of Trump&#8217;s $175B Golden Dome</a><span class="author" style="box-sizing: border-box; border: 0px solid rgb(229, 231, 235); --tw-scale-x: 1; --tw-scale-y: 1; --tw-pan-x: ; --tw-pan-y: ; --tw-pinch-zoom: ; --tw-scroll-snap-strictness: proximity; --tw-gradient-from-position: ; --tw-gradient-via-position: ; --tw-gradient-to-position: ; --tw-ordinal: ; --tw-slashed-zero: ; --tw-numeric-figure: ; --tw-numeric-spacing: ; --tw-numeric-fraction: ; --tw-ring-inset: ; --tw-ring-offset-width: 0px; --tw-ring-offset-color: #fff; --tw-ring-color: rgba(59,130,246,.5); --tw-ring-offset-shadow: 0 0 #0000; --tw-ring-shadow: 0 0 #0000; --tw-shadow: 0 0 #0000; --tw-shadow-colored: 0 0 #0000; --tw-blur: ; --tw-brightness: ; --tw-contrast: ; --tw-grayscale: ; --tw-hue-rotate: ; --tw-invert: ; --tw-saturate: ; --tw-sepia: ; --tw-drop-shadow: ; --tw-backdrop-blur: ; --tw-backdrop-brightness: ; --tw-backdrop-contrast: ; --tw-backdrop-grayscale: ; --tw-backdrop-hue-rotate: ; --tw-backdrop-invert: ; --tw-backdrop-opacity: ; --tw-backdrop-saturate: ; --tw-backdrop-sepia: ; --tw-contain-size: ; --tw-contain-layout: ; --tw-contain-paint: ; --tw-contain-style: ;"></li>
</ul>
Photo: Shutterstock

Eli Lilly's May Meltdown Is In History Books — Could June Seasonality Bring A Rebound?

Press Releases

Lilly announces transitions in executive leadership

Lilly plans to expand Purdue University collaboration with up to a $250 million investment to accelerate pharmaceutical innovation

Zepbound (tirzepatide) showed superior weight loss over Wegovy (semaglutide) in complete SURMOUNT-5 results published in The New England Journal of Medicine

Lilly's Kisunla (donanemab) receives marketing authorization in Australia for the treatment of early symptomatic Alzheimer's disease

Lilly announces details of presentations at 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

Lilly to expand its pain pipeline with acquisition of SiteOne Therapeutics

Lilly announces details of presentations at American Diabetes Association's (ADA) 85th Scientific Sessions

Lilly presents first clinical data for its investigational, next-generation FRα targeting ADC in platinum-resistant ovarian cancer at the 2025 ASCO Annual Meeting

Lilly to participate in Goldman Sachs 46th Annual Global Health Care Conference

Lilly to offer all approved doses of Zepbound (tirzepatide) single-dose vials through LillyDirect Self Pay Pharmacy Solutions

Axsome Therapeutics

AstraZeneca PLC - American Depositary Shares

AstraZeneca

BGM Group

Bristol-Myers Squibb Company Common Stock

Bristol-Myers Squibb

Corcept Therapeutics Incorporated - Common Stock

Corcept Therapeutics

Elanco Animal Health Incorporated Common Stock

Elanco Animal Health

GSK plc American Depositary Shares (Each representing two Ordinary Shares)

HUTCHMED (China) Limited - American Depositary Shares

HUTCHMED (China)

Haleon plc American Depositary Shares (Each representing two Ordinary Shares)

Haleon

Jazz Pharmaceuticals plc - Ordinary Shares

Jazz Pharmaceuticals

Johnson & Johnson

Merck & Co

Novo Nordisk

Novartis

Organon

Prestige Consumer Healthcare Inc. Common Stock

Prestige Consumer

Pfizer

Dr. Reddy's Laboratories Ltd Common Stock

Dr Reddy's Laboratories

Royalty Pharma plc - Class A Ordinary Shares

Royalty Pharma

Sanofi

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)

Takeda Pharmaceutical Co

Teva Pharmaceutical Industries Limited American Depositary Shares

Teva Pharmaceutical Indus

Verona Pharma plc - American Depositary Shares

Verona Pharma

Viatris

Zoetis

HSBC

Cantor Fitzgerald

Guggenheim

Morgan Stanley

Untitled design - 2025-03-31T165341.547

TNXP

VRTX

Tonix&#39;s Experimental Non-Opioid Analgesic Treatment For Fibromyalgia Could Start Bringing Relief Later This Year

Screenshot 2025-02-24 at 11.35.34 PM

BRTX

BioRestorative Therapies Receives FDA Fast Track Approval For BRTX-100 To Treat Chronic Lumbar Disc Disease

Screenshot 2024-11-20 at 6.30.30 PM

BioRestorative Ends Q3 In &#39;Strong&#39; Financial Position, Reports Positive Data For Its Phase 2 BRTX-100 Chronic Back Pain Trial

Screenshot 2024-09-30 at 9.13.36 PM

The Rush For Non-Addictive Painkillers To Counter The Opioid Crisis Puts Two Companies Closer To FDA Decisions

Screenshot 2024-09-10 at 4.29.40 PM

Armed With Its Patent Portfolio, BioRestorative Therapies Has Success In The Laboratory And At The Negotiating Table: Is Profitability Close Behind?

Screenshot 2024-08-22 at 5.32.58 PM

RDHL

RedHill&#39;s Opaganib Shows Diabetes And Obesity Potential With Positive In Vivo Results

Screenshot 2024-07-10 at 9.08.28 PM

AXSM

A Redux Of The Lyrica-Cymbalta Fibromyalgia War Of The 2010s May Look More Like David Vs. Goliath

Screenshot 2024-06-18 at 1.15.14 AM

BioRestorative Therapies Enters Preclinical Assessment Of Its Patented Stem-Cell Technology Prior To First-In-Human Studies

Screenshot 2024-05-16 at 5.52.00 PM

ELAB

Elevai Labs (NASDAQ: ELAB) Acquires Rights To Develop Muscle Loss Prevention Assets For Anticipated Use In Anti-Obesity Treatments, Launches Two New Subsidiaries

Comments

Eli Lilly

空売り

Eli Lilly (NYSE:LLY) 株価情報, 空売り情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル